RNF43 p.G659fs 通过 PI3K/AKT/mTOR 信号通路和 HLA-E 上调导致 MSI-high 结直肠癌中 NK 细胞功能障碍
RNF43 p.G659fs leads to natural killer cell dysfunction in MSI-high colorectal cancer through PI3K/AKT/mTOR signaling and HLA-E up-regulation.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:IL-15/IL-15Rα-secreting bioengineered adipocytes reactivate NK/CD8(+) T cells in ovarian and colon cancer ascites.
IL-15/IL-15Rα-secreting bioengineered adipocytes reactivate NK/CD8(+) T cells in ovarian and colon cancer ascites.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
恶性腹水(MA)是一项复杂的临床难题,与腹膜癌病(PC)的不良预后、化疗耐药及转移密不可分。然而,目前尚无用于管理或预防 PC 继发 MA 的标准治疗方法。
在本研究中,我们展示了一种生物工程化脂肪细胞,其包裹长链脂肪酸并同时分泌 IL-15 和 IL-15 受体(IL-15R),可显著延长 IL-15 的半衰期和生物活性。该生物工程化脂肪细胞由稳定转染 IL-15-P2A-IL-15R-T2A-mCherry cDNA 序列的 3T3-F442A 前脂肪细胞系组成,同时将二十二碳六烯酸(DHA)包裹于成熟脂肪细胞的脂滴中,在肿瘤细胞触发的脂解作用下释放至 MA 中。
我们证明,这些生物工程化脂肪细胞促使 MA 中的 NK/CD8+ T 细胞在应答 IL-15/IL-15R 复合物时发生特异性扩增和活化,从而逆转腹水免疫细胞的免疫抑制表型,使其能够识别并攻击癌细胞。这一协同治疗策略可实现对腹水免疫细胞的治疗性操控,恢复正常的免疫功能,并在卵巢癌和结肠癌中抑制癌细胞转移和肿瘤生长,同时将全身性不良反应降至最低。
Malignant ascites (MA) presents a complex clinical challenge, linked inextricably to poor prognosis, chemoresistance, and metastasis of peritoneal carcinomatosis (PC).
However, standard therapeutic approaches for managing or preventing MA secondary to PC remain unavailable.
Here we display that a bioengineered adipocyte, encapsulating long-chain fatty acids and concurrently secreting IL-15 and IL-15 receptor (IL-15R ), markedly extends the half-life and bioactivity of IL-15. The bioengineered adipocyte consists of an IL-15-P2A-IL-15R -T2A-mCherry cDNA sequence stable transfected 3T3-F442A preadipocyte cell line and dcosahexaenoic acid (DHA) are simultaneously encapsulated in the lipid droplets of mature adipocytes, which release it into the MA upon tumor cell-triggered lipolysis.
We demonstrate that the bioengineered adipocytes led to specific expansion and activation of NK/CD8 + T cells response to the IL-15/IL-15R complex in MA, thereby reversing immuno-suppressive phenotype of ascitic immune cells and enabling them to recognize and attack cancer cells. This synergistic therapeutic strategy exhibits therapeutical manipulation of the ascitic immune cells, restores normal immune functioning, and suppresses cancer cell metastasis and tumor growth in ovarian cancer and colon cancer, all while minimizing systemic adverse effects.
MEMBER ACCOUNT
登录成功会直接打开下一页。